Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

Authors
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Mar 01, 2010
Volume
28
Issue
7
Pages
1247–1253
Identifiers
DOI: 10.1200/JCO.2009.24.2099
PMID: 20124181
Source
Medline
License
Unknown

Abstract

This analysis confirms a small PFS advantage of high-dose imatinib, essentially among patients with KIT exon 9 mutations, but no OS advantage.

Report this publication

Statistics

Seen <100 times